Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients

Inclusion Criteria: * Received an allogeneic or autologous hematopoietic stem cell transplant (HSCT) using any conditioning regimen * Experienced new onset of at least one of the following respiratory symptoms ≤5 days before study Day 1: Nasal congestion or stuffiness, runny nose (rhinorrhoea), cough, or sore throat OR Worsening of at least one of those symptoms, if symptoms are chronic OR Wheezing, sputum production, pleuritic chest pain, increased respiratory rate, signs on chest auscultation, hypoxia, increased supplemental oxygen requirement or new infiltrates on chest X-ray/CT * A positive RSV diagnostic test * Provided written informed consent Exclusion Criteria: * Is intubated and requires invasive ventilation * Has received any investigational RSV vaccine after HSCT, or has received any monoclonal anti-RSV antibodies within 4 months or 5 half-lives before participation * Treatment with intravenous ribavirin * Positive for test for influenza or parainfluenza * Significant untreated bacteraemia or fungaemia * Significant untreated bacterial, fungal, or viral pneumonia * Precluded from participating as a result of treatment with another investigational drug or participation in another clinical trial * Other disease or condition which would preclude the subject's participation in a clinical trial * Is receiving an antiretroviral protease inhibitor * Has chronic, active hepatitis infection * Known alcohol or drug abuse